Clinical trials: Fasting Glucose
Type 2 Diabetes
Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes
The purpose of this study is to determine the optimal dose or doses of HM11260C, when administered once a week under the skin, to improve the control of blood sugar levels in patients with early-stage type 2 diabetes mellitus…
- Trial name
- NCT02057172
- Testing
- HM11260C, liraglutide
- Where
- United States
- Volunteers
- 254 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Diabetes, Diabetes Mellitus, Type 1
Comparing Insulin Aspart With Fast-acting Insulin Human in Subjects With Type 1 Diabetes
This trial is conducted in Japan. The aim of the trial is to compare pharmacokinetics (at which rate the body eliminates the substance from the body) of insulin aspart with fast-acting insulin human following intravenous (IV)…
- Trial name
- NCT01269606
- Testing
- insulin aspart, insulin human
- Where
- Japan
- Volunteers
- 13 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
An Observational Study to Evaluate Tolerability of Canagliflozin and Sulphonylurea in Type 2 Diabetes Patients During Ramadan
The primary purpose of this study is to describe the tolerability of canagliflozin and any sulphonylurea (each administered with metformin with or without a DPP-4 inhibitor), in terms of the percentage of patients with at least…
- Trial name
- CRATOS (NCT02737657)
- Where
- 9 sites in Kuwait, Lebanon and 1 more
- Volunteers
- 379 people
- Sponsor
- Janssen-Cilag International NV
Diabetes Mellitus, Type 1
Effect of Fiasp® in Type 1 Diabetes Treatment
Fiasp® is a meal-time insulin that has been available in Sweden since June 2017. This study will investigate the effectiveness of Fiasp® in treating Type 1 Diabetes Mellitus.
- Trial name
- NCT03895515
- Testing
- Fiasp®
- Where
- Sweden
- Volunteers
- 178 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262)
This is a study comparing the incidence of hypoglycemia while using sitagliptin treatment versus sulfonylurea (SU) treatment in participants with type 2 diabetes mellitus (T2DM) who regularly take an SU drug, and choose to fast…
- Trial name
- NCT01340768
- Testing
- Sitagliptin, Sulfonylurea, Metformin
- Volunteers
- 870 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
A Research Study to Look at How Faster Aspart Works in Chinese People With Type 1 Diabetes or Type 2 Diabetes
This study looks at how faster aspart reaches and stays in the blood after injection in Chinese people with type 1 diabetes or type 2 diabetes, compared to the reference product called NovoRapid®.
- Trial name
- NCT04698018
- Testing
- Faster Aspart, Novo Rapid
- Where
- 3 sites in Germany, Hong Kong
- Volunteers
- 23 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Long-term Safety Study of Vildagliptin in Patients With Type 2 Diabetes
This study is designed to demonstrate the long-term safety of vildagliptin in patients with type 2 diabetes. This study will study vildagliptin as add-on therapy with metformin, thiazolidinedione, α-glucosidase inhibitor (α-GI)…
- Trial name
- NCT01159249
- Testing
- Vildagliptin
- Where
- 24 sites in Japan
- Volunteers
- 245 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes, Diabetes Mellitus, Type 1
A Trial Comparing the Pharmacokinetic Properties of Fast-acting Insulin Aspart Between Children, Adolescents and Adults With Type 1 Diabetes
The study is done to compare how faster aspart is taken up, broken down and removed from the body between different age groups (children [6-11 years], adolescents [12-17 years] and adults [18-64 years]) who have diabetes.
- Trial name
- NCT03407599
- Testing
- Faster aspart, Insulin aspart (NovoRapid®)
- Where
- Germany
- Volunteers
- 46 people
- Sponsor
- Novo Nordisk A/S
Time Restricted Feeding
Effect of 14:10 Time-Restricted Eating on Body Weight and Metabolic Markers
The purpose of this study is to investigate the effect of engaging in time restricted eating schedule on body weight, blood glucose, and ketones (breath acetone) in individuals with obesity.
- Trial name
- NCT04492930
- Testing
- 14:10 Regimen, 12:12 Regimen
- Where
- United States
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- Jenny Craig, Inc.
Type 1 Diabetes Mellitus
A Trial to Investigate Post Prandial Blood Glucose Control With Fast-acting Human Insulin HinsBet® Compared to Insulin Lispro (Humalog®) and Regular Human Insulin (Huminsulin® Normal) After Ingestion of a Standardized Meal in Subjects With T1DM
This is a 2 centres, randomised, double blind, three-treatment, three-period cross-over trial in subjects with type 1 diabetes mellitus.
- Trial name
- NCT02739906
- Testing
- BioChaperone Human Insulin (HinsBet®), Insulin Lispro (Humalog®), Regular human insulin (Huminsulin® Normal)
- Where
- 2 sites in Germany
- Volunteers
- 36 people
- Sponsor
- Adocia
Type 2 Diabetes Mellitus
Evaluate the Drug-drugs Interaction Between Lobeglitazone 0.5mg and Empagliflozin 25mg
A Clinical Trial to evaluate the Pharmacokinetics and Tolerability of CKD-398
- Trial name
- NCT04869800
- Testing
- CKD-398, CKD-501, D745
- Where
- South Korea
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Type 2 Diabetes
Study to Compare the Bioavailability of Extended Release Metformin HCl Tablet Versus Glucophage XR® Tablets in Healthy Human Volunteers Under Fasting Condition
Objective: To compare the bioavailability of Extended Release Metformin HCl Tablet(Test formulation, Torrent Pharmaceuticals Ltd.,India) versus Glucophage XR® Tablets ( Reference formulation, Bristol-Myers Squibb Company, USA) in…
- Trial name
- NCT01089166
- Testing
- Metformin
- Where
- India
- Sponsor
- Torrent Pharmaceuticals Limited
Type 2 Diabetes
Efficacy and Safety of Metformin Glycinate Compared to Metformin Hydrochloride on the Progression of Type 2 Diabetes
Phase III study to evaluate the efficacy and safety of the treatment. Two-arm, prospective, longitudinal, double-blind, multicenter randomized clinical trial.
- Trial name
- COMETII (NCT04943692)
- Testing
- Metformin glycinate, Metformin Hydrochloride
- Where
- Mexico
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Laboratorios Silanes S.A. de C.V.
Type 2 Diabetes Mellitus (T2DM)
Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg in Fast Condition
Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg in fast condition.
- Trial name
- NCT07372118
- Testing
- Empagliflozin / Metformin HCl XR Tablets, Synjardy® XR (empagliflozin and metformin hydrochloride extended-release Tablets)
- Where
- India
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Type 2 Diabetes Mellitus (T2DM)
Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263)
This study will examine whether the incidence of hypoglycemia in patients fasting for Ramadan is lower when treated with sitagliptin as compared to sulfonylurea treatment.
- Trial name
- NCT01131182
- Testing
- Sitagliptin phosphate, Comparator: Sulfonylurea, Metformin
- Volunteers
- 1,147 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
A Study to Evaluate the Pharmacokinetics and Safety of BR3409 and Co-administration of BR3409-1 and BR3409-2 in Healthy Volunteers Under Fasting Conditions
The purpose of this clinical study is to evaluate the pharmacokinetics and safety of BR3409 and co-administration of BR3409-1 and BR3409-2 in healthy volunteers Under Fasting Conditions
- Trial name
- NCT06879158
- Testing
- BR3409, BR3409-1, BR3409-2
- Where
- South Korea
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Type 2 Diabetes Mellitus (T2DM), Cardiovascular Diseases
Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCl25 mg/5 mg/1000 mg Extended Release Tablet Versus Trijardy® XR 25 mg/5 mg/1000 mg Extended- Release Tablets
An open label, randomized, two-period, two treatment, two-sequence, crossover, balanced, single dose oral bioequivalence study to compare Empagliflozin/ Linagliptin/ Metformin HCl 25 mg/5 mg/1000 mg Extended Release Tablet versus…
- Trial name
- NCT07872358
- Testing
- Empagliflozin/Linagliptin/Metformin HCl Extended Release Tablet, Trijardy® XR Tablets
- Where
- India
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Coronary Arteriosclerosis, Diabetes Mellitus, Type 2
Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets
European physicians tend to always use the lowest dose of statins to initiate therapy even in subjects who require large reductions in cholesterol.
- Conditions
- Coronary Arteriosclerosis, Diabetes Mellitus, Type 2, Cerebrovascular Accident, Dyslipidemia
- Trial name
- ACTFAST 2 (NCT00442325)
- Testing
- Atorvastatin (Lipitor)
- Where
- 32 sites in Greece, Hungary and 6 more
- Volunteers
- 595 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Type 2 Diabetes Mellitus
A Study to Compare the Pharmacokinetics and the Safety Between a Fixed-dose Combination Administration of "BR3005" and Co-administration of "BR3005-1" and "BR3005-2" Under Fasting Conditions in Healthy Adult Volunteers
The objective of this clinical study is to compare the pharmacokinetics and the safety between a fixed-dose combination administration of "BR3005" and co-administration of "BR3005-1" and "BR3005-2" under fasting conditions in…
- Trial name
- NCT06289920
- Testing
- BR3005, BR3005-1, BR3005-2
- Where
- South Korea
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Diabetes Mellitus, Type 2
OXEMET™ 1000 mg Coated Tablets (Metformin Hydrochloride) Bioequivalence Study. OXEMET (TM) is a Trademark of the GlaxoSmithKline Group of Companies. GLAFORNIL(TM) is a Trademark of Merck.
This is an open-label, single-center, randomized, 2-way crossover study to evaluate the bioequivalence of OXEMET™ 1000 mg coated tablets, relative to 1000 mg of the reference product administered as two 500 mg tablets, under…
- Trial name
- NCT01842620
- Testing
- Metformin
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline